INVITRIA, INC. – Trademark Portfolio
Entity Type: 03
INVITRIA, INC. holds 31 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 30 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 3 Nice Classification classes. Currently, 26 trademarks are registered and 2 are pending. Notable registered marks include EXBUMIN, LYSOBAC, OPTIFRZ, CURAVIVE, and INVITRIA. The owner is based in JUNCTION CITY, KS.
2718 INDUSTRIAL DRIVE
JUNCTION CITY, KS 66441
Showing of trademarks Trademarks
Trademark Classifications
INVITRIA, INC.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does INVITRIA, INC. have?
INVITRIA, INC. has 31 U.S. trademarks filed with the USPTO. Of these, 26 registered, 2 pending, 3 cancelled.
What trademark classes does INVITRIA, INC. file in?
INVITRIA, INC. files trademarks across 3 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are INVITRIA, INC.'s most well-known trademarks?
INVITRIA, INC.'s registered trademark portfolio includes well-known marks such as EXBUMIN, LYSOBAC, OPTIFRZ, CURAVIVE, and INVITRIA. These are among 26 currently registered trademarks in the portfolio.
What is INVITRIA, INC.'s trademark registration success rate?
INVITRIA, INC. has a 90% trademark registration rate, with 26 out of 29 resolved applications resulting in successful registration. Currently, 2 applications are pending review.